Summary

Codon 12 KRAS mutations are an independent predictor of time to recurrence (TTR) and disease-free survival (DFS) in patients with Stage III colon cancer who received adjuvant treatment. This article presents data from a post hoc analysis of the Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed by Surgery trial [PETACC8; Taieb J et al. Ann Oncol 2014 (abstr O-0024)].